Table 1.
Baseline characteristics of the 347 patients
| Variable | Patients (%)/median (P25–P75)a | Variable | Patients (%)/median (P25–P75) | ||
|---|---|---|---|---|---|
| Sex | Male | 290 (83.6) | Child class | A | 335 (96.5) |
| Female | 57 (16.4) | B | 12 (3.5) | ||
| Age (years) | ≥ 60 | 95 (27.4) | Performance status | 1 | 144 (41.3) |
| < 60 | 252 (72.6) | 0 | 203 (58.2) | ||
| HBsAg | Positive | 300 (86.5) | BCLC staging | Ad | 175 (50.4) |
| Negative | 47 (13.5) | B | 17 (4.9) | ||
| Liver cirrhosis | Yes | 222 (64) | C | 155 (44.7) | |
| No | 125 (36) | AJCC staging | I | 166 (47.8) | |
| Portal vein invasion | Yes | 21 (6.1) | II | 136 (39.2) | |
| No | 326 (93.9) | IIIe | 45 (13) | ||
| Ascites | Yes | 11 (3.2) | CNLC staging | I | 291 (83.9) |
| No | 336 (96.8) | II | 33 (9.5) | ||
| Ablation or TACE | Yes | 188 (54.2) | III | 23 (6.6) | |
| No | 159 (45.8) | Neutrophil count | 3.6 (2.56–4.72) | ||
| AFP (ng/ml) | > 400 | 132 (38) | Lymphocyte count | 1.45 (1.03–1.84) | |
| ≤ 400 | 215 (62) | Platelet count | 150 (109–205) | ||
| Tumor capsule | Yes | 304 (87.6) | γ-GT | 60 (36–115) | |
| No | 43 (12.4) | AST | 37 (27–53) | ||
| Tumor number | ≥ 2 | 42 (12.1) | Total bilirubin | 15.2 (12–21.2) | |
| 1 | 305 (87.9) | Prothrombin time | 11.7 (11–12.4) | ||
| Tumor size (cm) | > 5 | 168 (48.4) | Albumin | 44 (40.7–46.7) | |
| ≤ 5 | 179 (51.6) | Fibrinogen | 2.61 (2.13–3.27) | ||
| MVIb | Yes | 172 (49.6) | NLR | 2.44 (1.71–3.37) | |
| No | 175 (50.4) | PLR | 104.46(74.69–150.52) | ||
| Cell differentiation | Poor | 35 (10.1) | GPR | 0.45 (0.22–0.88) | |
| Moderate | 283 (81.6) | ALR | 26.97 (17.02–44.74) | ||
| Well | 29 (8.4) | FAR | 0.06 (0.05–0.08) | ||
| MKIc | Yes | 33 (9.5) | |||
| No | 314 (90.5) |
aP25–P75: (lower quartile—upper quartile)
bMVI: microvascular invasion
cMKI: multiple kinase inhibitor
dNine patients with BCLC stage 0 were merged into the BCLC stage A group
eFive patients with AJCC stage IV were merged into the AJCC stage III group